The Product Trials Catalyst gives product developers access to a statewide clinical network through a single IRB and contract approval process — so trials start sooner and enroll faster.
instead of negotiating site by site
Sponsors must negotiate separately with each and every trial site — repeating ethics reviews, contracts and budgets before a single patient can enroll.
Finding and enrolling enough eligible participants on time is one of the most common reasons trials stall.
of trials fail to meet recruitment timelines
of sites fail to recruit even one participant
of dollars per day in lost opportunity for sponsors, as recruitment delays add months to years to product development
The Product Trials Catalyst replaces dozens of separate negotiations with a single path to approval.
One institutional review board approval covers participating sites across the network.
One contracting process replaces separate negotiations with each trial site.
Reach patients at 67 hospitals and more than 1,000 outpatient facilities to meet enrollment targets.
trials supported by the Product Trials Catalyst
product achieved FDA clearance, with plans for an additional trial
in gross income to date (approximate)
The Product Trials Catalyst is a program of the Regenerative Medicine Engine in North Carolina, a U.S. National Science Foundation Regional Innovation Engine.
